# CheckMate 722 (NCT02864251)

> A Study of Nivolumab + Chemotherapy or Nivolumab + Ipilimumab Versus Chemotherapy in Non-Small Cell Lung Cancer (NSCLC) Participants With Epidermal Growth Factor Receptor (EGFR) Mutation Who Failed 1L or 2L EGFR Tyrosine Kinase Inhibitor (TKI) Therapy

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT02864251
- Phase: PHASE3
- Status: COMPLETED
- Sponsor: Bristol-Myers Squibb
- Conditions: Non-Small-Cell Lung Carcinoma
- Interventions: Nivolumab; Ipilimumab; Pemetrexed; Cisplatin; Carboplatin
- Enrollment: 367
- Primary outcome: Progression Free Survival (PFS) by Blinded Independent Centralized Review (BICR)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- Podcasts: 12
- X threads: 11
- YouTube: 9

## Order

Deep, $1,950, price fixed at order: https://www.erudio.com/contact?report=checkmate-722-nct02864251

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT02864251", "email": "<work email>"}; the inbox owner confirms by the emailed link.